PARP1 and cancer: Increased sensitivity of cells with reduced PARP1 activity to the TOP1 inhibitor camptothecin, irinotecan and topotecan, which is used as a cancer therapeutic agent, raised a potential combinatorial treatment of TOP1i with PARPi (11,17,48–52).